Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 12, 2022

SELL
$11.56 - $19.76 $329,032 - $562,428
-28,463 Closed
0 $0
Q4 2021

Feb 03, 2022

BUY
$11.18 - $15.46 $1,118 - $1,546
100 Added 0.35%
28,463 $394,000
Q3 2021

Nov 02, 2021

SELL
$14.21 - $17.65 $69,657 - $86,520
-4,902 Reduced 14.74%
28,363 $407,000
Q2 2021

Aug 10, 2021

SELL
$9.5 - $17.24 $142,918 - $259,358
-15,044 Reduced 31.14%
33,265 $525,000
Q1 2021

May 07, 2021

BUY
$7.37 - $13.61 $45,060 - $83,211
6,114 Added 14.49%
48,309 $491,000
Q4 2020

Feb 04, 2021

BUY
$3.37 - $8.61 $20,927 - $53,468
6,210 Added 17.26%
42,195 $314,000
Q3 2020

Oct 29, 2020

SELL
$3.43 - $5.53 $59,750 - $96,332
-17,420 Reduced 32.62%
35,985 $123,000
Q2 2020

Jul 27, 2020

BUY
$1.9 - $5.61 $101,469 - $299,602
53,405 New
53,405 $254,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.41B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track Cambridge Investment Research Advisors, Inc. Portfolio

Follow Cambridge Investment Research Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cambridge Investment Research Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cambridge Investment Research Advisors, Inc. with notifications on news.